David Newman, GlaxoSmithKline
S
Jeffrey Aronin, Ovation
Vlad Hogenhuis, Merck
Safi Bahcall, Synta Pharmaceuticals
Alan Tennenberg; Tibotec, J&J
Greg Parekh, Novartis
J. Martin Jernigan, Novo Nordisk
The Buddy System
Jean-Marc Niemetz on forming partnerships with the industry's major stakeholders
Blair Gibson, Merck
Julie McHugh, J&J
Rich Tillyer, Merck
Jared Silverman, Cubist
Ameet Mallik, Novartis
John Orwin, Genentech
Angela Moskow, Sanofi-Aventis
Tariq Arshad, Pfizer
Suzanne Delaney, AstraZeneca
Susanne Schaffert, Novartis
Candidates Target Pharma
US presidential hopefuls look to comparative effectiveness analysis to address price and access issues
Evan Morris, Roche
Chris Claiborne, Millennium
Rob Perez, EVP and COO, Cubist Pharmaceuticals
John Shamsey, Bristol-Myers Squibb
Chantix Under Fire
A new study ranks Pfizer's anti-smoking drug as number one in generating adverse event reports. That's bad news for Pfizer-but in the long run, what does it really mean?
Survey: Pharma Layoffs Finding Jobs
While pharma groans at the endless stream of layoffs, one headhunting firm has some encouraging news: Pharma might be cutting costs, but it's also hiring.
Google Launches Health Site
Can pharma take advantage of new healthcare data storage sites such as Google Health and Microsoft?s Health vault? Everyone?s curious, but no one?s talking.
Dial FDA: Marketers Face Added DTC Requirements
Feds consider adding an 800 number to television ads for adverse event reporting. Does this shine light on DTC ads while pushing public health goals? Industry is mum on the topic
Red Cross Gets OK to Market Emblem
American Red Cross scores a win against Johnson & Johnson in a legal battle over the use of one of the healthcare?s most recognizable symbols
Revised Prix Galien brochure
Revised Prix Galien Brochure
Shire Reminder Promo a No No
FDA takes the opportunity to remind industry what reminder ads are, as promotional material for Shire's Fosrenol is deemed in violation of advertising rules
